DK2895513T3 - Fc-indeholdende polypeptider med ændret glykosylering og reduceret effektorfunktion - Google Patents
Fc-indeholdende polypeptider med ændret glykosylering og reduceret effektorfunktion Download PDFInfo
- Publication number
- DK2895513T3 DK2895513T3 DK13766833.1T DK13766833T DK2895513T3 DK 2895513 T3 DK2895513 T3 DK 2895513T3 DK 13766833 T DK13766833 T DK 13766833T DK 2895513 T3 DK2895513 T3 DK 2895513T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- binding
- domain
- glycan
- residue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Isoleret antistof, der omfatter et humant IgGl Fc-domæne, hvori det humane IgGl Fc-domæne omfatter en glykosyleret asparaginrest i aminosyreposition 298 ifølge EU-nummereringen; og en serin- eller threoninrest i aminosyreposition 300 ifølge EU-nummereringen.
2. Antistof ifølge krav 1, hvori det humane IgGl Fc-domæne desuden omfatter en alaninrest i aminosyreposition 299 ifølge EU-nummereringen; eller det humane IgGl Fc-domæne desuden omfatter en glutaminrest i aminosyreposition 297 ifølge EU-nummereringen .
3. Antistof ifølge krav 1 eller 2, hvori én eller flere af de følgende betingelser er opfyldt: a) sidekæden af asparaginresten i aminosyreposition 298 ifølge EU-nummereringen er bundet til en glycan gennem en β-glycosylamidbinding b) sidekæden af asparaginresten i aminosyreposition 298 ifølge EU-nummereringen er bundet til en glycan gennem en β-glycosylamidbinding, og: i) glycanen er en biantennisk glycan ii) glycanen er en naturligt forekommende pattedyr-glycoform iii) glycanen omfatter en reaktiv aldehydgruppe iv) glycanen omfatter en oxyderet saccharidrest, der omfatter en reaktionsdygtig aldehydgruppe, eller v) glycanen er bundet til en effektordel.
4. Antistof ifølge krav 3, hvori én eller flere af de følgende betingelser er opfyldt: a) den oxyderede saccharidrest er en terminal sialinsyre eller galactose b) effektordelen er et cytotoksin c) effektordelen er et diagnostisk middel d) effektordelen er et terapeutisk middel, hvori det terapeutiske middel eventuelt er valgt fra den gruppe, der består af en lægemiddeldel, en prodrug-del og en radioaktivt
mærket forbindelse e) effektordelen omfatter en pH-følsom linker, en disulfidlinker, en enzymfølsom linker eller en anden spaltbar linkerdel, der frigiver effektordelen fra antistoffet, når den spaltes, og f) effektordelen omfatter en linkerdel, der er valgt fra den gruppe, der består af de linkerdele, som er afbildet nedenfor: (i) g H pi rS' i (il) o Λ , (fi' x O"' 7 A JL. I N X S H R R (111) o " 1 ff°A/ (iv) OH HO. Λ XOOH V γ Ηβ*" V"0 i (V) O "x' o τΎκ o MH 0 MiHj (vi) (vir)
Α η 0 ιί'Υ'”^ yVX ».»V-ΑΥΧΥ 1 »X1 Μ °'° U □ ° Ί ^ΗΗ ϋΥ.Η; (viii) h γ» s η^°ΛΝΗΥ°γ°^Λ"'ΛΧ\>^ Pyv^AVY [ 1 1 ΪΧ I IJ Α 1 V ο ο 0 Λ X Ο ΝΗ og (ix) s so -x>J-XH λ ΥΥ'°Α"^"γΛ?''ϊ^^ Y^Yr ο”y tiγ Χη 'ΜΗ Υνη, hvori R1, R2, R3, R4 og R5 er H, alkyl eller aryl.
5. Antistof ifølge et hvilket som helst af kravene 3-4, hvori én eller flere af de følgende betingelser er opfyldt: a) cytotoxinet er valgt fra den gruppe cytotoxiner, der er afbildet nedenfor: o /\ H0 YP hii I^Y^^iYfN_ d h ? J \ i i μ VYY ' o Y. i o-o a T T HIN A^An x O 0 yY hX^Y^?Qy^VyKy^ y ογν λΛυ 0 cy o cy o U Yz 1 o å 1 o.o <y o OH „ρρχγγχγο γχΑΥΥ 0 yy cy o cy o I 0 yx I y 0 ox o yyypy'iO 1 o y\ 1 cy o Cy o A^Vf-W-v, H o Å 1 o °- 0 W i , ΥυΥΥΥϊ A" ΛΥΥΡΥΥ^ H S Λ 1 h o X 0 H 5 A I cy S °x 0 yY ΑυΥΥΥγ^ H S A 1 V 0 1
rvNH2 H S x i 5 °-0 XÅX H J Λ 1 U °" ° ° OMe, vUU — Cl\ t-\ Η O θ^ΧΧχ HO #— N—/ /—OH h-co XX? /—1 ✓S. JL. S -ΟΜθ J·. |l Kl / *\ <"ί ^^Άμ·Ν /"OMe I I 01 N , ΜθΟ , O JD Ηο,>Γχχο— γΚΛ ^/χ^Α,ΧνI ' Me0 ΡχΎκ Αλ/ Γ H Q χχ °·" --LxA I (*\i_i I I I HO H I 0H , 1 MeO , og XXhA^ J | ^'''’COOH hvori Ri= alkyl, aryl, alkoxy, aryloxy, R2, R3= alkyl, aryl b) effektordelen er bundet til en saccharidrest i glycanen gennem en oxim- eller en hydrazonbinding; og c) effektordelen er bundet til en saccharidrest i glycanen gennem en oxim- eller hydrazonbinding, hvori saccharidresten er en terminal sialinsyre- eller galactoserest i glycanen.
6. Antistof ifølge et hvilket som helst af kravene 1-5, der omfatter et humant IgGl Fc-domæne, som omfatter en asparaginrest i position 297 ifølge EU-nummereringen; en glycosyleret asparaginrest i position 298 ifølge EU-nummereringen; en alaninrest i aminosyreposition 299 ifølge EU-nummereringen; og en serinrest i aminosyreposition 300 ifølge EU-nummereringen.
7. Sammensætning, der omfatter et antistof ifølge et hvilket som helst af de foregående krav og et farmaceutisk acceptabelt bærestof eller hjælpestof.
8. Effektiv mængde af sammensætningen ifølge krav 7 til anvendelse som lægemiddel.
9. Isoleret polynukleotid, der koder for et antistof ifølge et hvilket som helst af kravene 1-6.
10. Vektor, der omfatter et polynukleotid ifølge krav 9.
11. Værtscelle, der omfatter et polynukleotid ifølge krav 9 eller en vektor ifølge krav 10.
12. Fremgangsmåde til fremstilling af et antistof, der omfatter ekspression af et polynukleotid ifølge krav 9 eller en vektor ifølge krav 10 i en celle.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/003819 WO2013037484A2 (en) | 2011-09-12 | 2012-09-12 | Anti-aplhabetatcr antibody |
US201361776715P | 2013-03-11 | 2013-03-11 | |
PCT/US2013/059481 WO2014043361A1 (en) | 2012-09-12 | 2013-09-12 | Fc containing polypeptides with altered glycosylation and reduced effector function |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2895513T3 true DK2895513T3 (da) | 2018-09-03 |
Family
ID=50278674
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18166377.4T DK3366705T3 (da) | 2012-09-12 | 2013-09-12 | Fc-indeholdende polypeptider med ændret glycosylering og reduceret effektorfunktion |
DK13766833.1T DK2895513T3 (da) | 2012-09-12 | 2013-09-12 | Fc-indeholdende polypeptider med ændret glykosylering og reduceret effektorfunktion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18166377.4T DK3366705T3 (da) | 2012-09-12 | 2013-09-12 | Fc-indeholdende polypeptider med ændret glycosylering og reduceret effektorfunktion |
Country Status (35)
Country | Link |
---|---|
EP (3) | EP2895513B1 (da) |
JP (1) | JP6438397B2 (da) |
KR (3) | KR102185151B1 (da) |
CN (2) | CN110590953A (da) |
AU (1) | AU2013315499B2 (da) |
CA (1) | CA2884762C (da) |
CL (1) | CL2015000606A1 (da) |
CR (1) | CR20150147A (da) |
CY (1) | CY1120909T1 (da) |
DK (2) | DK3366705T3 (da) |
DO (1) | DOP2015000050A (da) |
EA (2) | EA202091166A1 (da) |
EC (1) | ECSP15014133A (da) |
ES (2) | ES2684549T3 (da) |
FI (1) | FI3366705T3 (da) |
HK (1) | HK1207389A1 (da) |
HR (2) | HRP20230623T1 (da) |
HU (2) | HUE039337T2 (da) |
IL (4) | IL237640B (da) |
LT (2) | LT2895513T (da) |
MA (1) | MA37949B1 (da) |
MX (2) | MX366103B (da) |
MY (1) | MY170126A (da) |
NZ (1) | NZ705983A (da) |
PE (1) | PE20150650A1 (da) |
PH (1) | PH12015500528A1 (da) |
PL (2) | PL2895513T3 (da) |
PT (2) | PT3366705T (da) |
RS (2) | RS57748B1 (da) |
SG (2) | SG11201501521TA (da) |
SI (2) | SI3366705T1 (da) |
TN (1) | TN2015000085A1 (da) |
UA (1) | UA116995C2 (da) |
WO (1) | WO2014043361A1 (da) |
ZA (1) | ZA201501417B (da) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
EP4063389A3 (en) | 2013-03-11 | 2022-12-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
US10995148B2 (en) | 2014-03-19 | 2021-05-04 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
WO2015157446A1 (en) * | 2014-04-08 | 2015-10-15 | University Of Georgia Research Foundation Inc. | Site-specific antibody-drug glycoconjugates and methods |
JP6666336B2 (ja) * | 2014-06-12 | 2020-03-13 | シー・エス・ピー・シー ドフェン コーポレーションCspc Dophen Corporation | 酵素的方法による均一抗体薬物コンジュゲート |
ES2838680T3 (es) * | 2014-10-09 | 2021-07-02 | Genzyme Corp | Conjugados de anticuerpo-fármaco glucomodificados |
TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
JP7042816B2 (ja) | 2016-11-08 | 2022-03-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
GB201717446D0 (en) * | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
CA3084385A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
AU2019249273A1 (en) | 2018-04-06 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Methods of treatment using a leptin receptor agonist antibody |
JP1640846S (da) * | 2018-10-16 | 2019-09-09 | ||
JP2022512904A (ja) | 2018-11-21 | 2022-02-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗Staphylococcus抗体およびその使用 |
MA54545A (fr) | 2018-12-21 | 2021-10-27 | Regeneron Pharma | Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci |
CN113474370A (zh) | 2019-02-01 | 2021-10-01 | 瑞泽恩制药公司 | 抗IL2受体γ抗原结合蛋白 |
KR20230008830A (ko) | 2020-05-08 | 2023-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법 |
CN116670170A (zh) | 2020-09-15 | 2023-08-29 | 瑞泽恩制药公司 | Lepr激动剂用于疼痛的用途 |
KR20220052098A (ko) | 2020-10-20 | 2022-04-27 | 주식회사 엘지에너지솔루션 | 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법 |
KR102576252B1 (ko) * | 2021-04-07 | 2023-09-11 | 아주대학교산학협력단 | 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물 |
WO2023069711A1 (en) * | 2021-10-22 | 2023-04-27 | Trustees Of Tufts College | Fap-targeted neutron capture agents, and uses and formulations related thereto |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
WO2024107759A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
EP1487879B1 (en) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
DK1534335T4 (da) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | Fcgammariib-specifikke antistoffer og fremgangsmåder til anvendelse deraf |
KR100960560B1 (ko) | 2002-09-27 | 2010-06-03 | 젠코어 인코포레이티드 | 최적화된 Fc 변이체 및 그의 제조 방법 |
SI1562972T1 (sl) | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
KR100758755B1 (ko) * | 2003-06-12 | 2007-09-14 | 일라이 릴리 앤드 캄파니 | Glp-1 유사체 융합 단백질 |
US8399618B2 (en) * | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
SI1706424T1 (sl) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Variante fc regij |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
WO2006019447A1 (en) | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
EP1799700A4 (en) * | 2004-09-27 | 2009-02-11 | Centocor Inc | SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するFc変異体 |
EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
CA2614046C (en) | 2005-06-30 | 2018-05-15 | Centocor, Inc. | Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7833260B2 (en) | 2006-07-20 | 2010-11-16 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
AU2008207898B2 (en) * | 2007-01-23 | 2012-05-03 | Xencor, Inc | Optimized CD40 antibodies and methods of using the same |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP2444491B1 (en) * | 2008-04-21 | 2016-11-16 | Novo Nordisk Healthcare Ag | Hyperglycosylated human coagulation factor IX |
EP2679681B2 (en) * | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
UY34317A (es) * | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
-
2013
- 2013-09-12 HR HRP20230623TT patent/HRP20230623T1/hr unknown
- 2013-09-12 EP EP13766833.1A patent/EP2895513B1/en active Active
- 2013-09-12 FI FIEP18166377.4T patent/FI3366705T3/fi active
- 2013-09-12 PE PE2015000327A patent/PE20150650A1/es active IP Right Grant
- 2013-09-12 RS RS20180981A patent/RS57748B1/sr unknown
- 2013-09-12 KR KR1020157009038A patent/KR102185151B1/ko active IP Right Grant
- 2013-09-12 DK DK18166377.4T patent/DK3366705T3/da active
- 2013-09-12 SG SG11201501521TA patent/SG11201501521TA/en unknown
- 2013-09-12 ES ES13766833.1T patent/ES2684549T3/es active Active
- 2013-09-12 KR KR1020227025572A patent/KR20220110855A/ko not_active Application Discontinuation
- 2013-09-12 PT PT181663774T patent/PT3366705T/pt unknown
- 2013-09-12 LT LTEP13766833.1T patent/LT2895513T/lt unknown
- 2013-09-12 SG SG10201701831VA patent/SG10201701831VA/en unknown
- 2013-09-12 SI SI201332053T patent/SI3366705T1/sl unknown
- 2013-09-12 KR KR1020207033737A patent/KR102426488B1/ko active IP Right Grant
- 2013-09-12 CA CA2884762A patent/CA2884762C/en active Active
- 2013-09-12 PT PT13766833T patent/PT2895513T/pt unknown
- 2013-09-12 MY MYPI2015000513A patent/MY170126A/en unknown
- 2013-09-12 SI SI201331144T patent/SI2895513T1/sl unknown
- 2013-09-12 AU AU2013315499A patent/AU2013315499B2/en active Active
- 2013-09-12 PL PL13766833T patent/PL2895513T3/pl unknown
- 2013-09-12 MX MX2015003234A patent/MX366103B/es active IP Right Grant
- 2013-09-12 EP EP23164492.3A patent/EP4223783A3/en active Pending
- 2013-09-12 EP EP18166377.4A patent/EP3366705B1/en active Active
- 2013-09-12 HU HUE13766833A patent/HUE039337T2/hu unknown
- 2013-09-12 DK DK13766833.1T patent/DK2895513T3/da active
- 2013-09-12 HU HUE18166377A patent/HUE062876T2/hu unknown
- 2013-09-12 PL PL18166377.4T patent/PL3366705T3/pl unknown
- 2013-09-12 MA MA37949A patent/MA37949B1/fr unknown
- 2013-09-12 ES ES18166377T patent/ES2950509T3/es active Active
- 2013-09-12 EA EA202091166A patent/EA202091166A1/ru unknown
- 2013-09-12 WO PCT/US2013/059481 patent/WO2014043361A1/en active Application Filing
- 2013-09-12 NZ NZ705983A patent/NZ705983A/en unknown
- 2013-09-12 JP JP2015532046A patent/JP6438397B2/ja active Active
- 2013-09-12 LT LTEP18166377.4T patent/LT3366705T/lt unknown
- 2013-09-12 EA EA201590545A patent/EA035987B1/ru unknown
- 2013-09-12 RS RS20230536A patent/RS64317B1/sr unknown
- 2013-09-12 CN CN201910721123.7A patent/CN110590953A/zh active Pending
- 2013-09-12 CN CN201380058863.8A patent/CN104797601B/zh active Active
- 2013-12-09 UA UAA201503410A patent/UA116995C2/uk unknown
-
2015
- 2015-03-02 ZA ZA2015/01417A patent/ZA201501417B/en unknown
- 2015-03-05 DO DO2015000050A patent/DOP2015000050A/es unknown
- 2015-03-06 TN TNP2015000085A patent/TN2015000085A1/fr unknown
- 2015-03-09 IL IL237640A patent/IL237640B/en active IP Right Grant
- 2015-03-11 PH PH12015500528A patent/PH12015500528A1/en unknown
- 2015-03-11 CL CL2015000606A patent/CL2015000606A1/es unknown
- 2015-03-12 MX MX2019007753A patent/MX2019007753A/es unknown
- 2015-03-19 CR CR20150147A patent/CR20150147A/es unknown
- 2015-04-10 EC ECIEPI201514133A patent/ECSP15014133A/es unknown
- 2015-08-19 HK HK15108040.6A patent/HK1207389A1/xx unknown
-
2018
- 2018-08-23 CY CY181100880T patent/CY1120909T1/el unknown
- 2018-08-23 HR HRP20181354TT patent/HRP20181354T1/hr unknown
-
2019
- 2019-11-28 IL IL271027A patent/IL271027B/en active IP Right Grant
-
2020
- 2020-08-23 IL IL276866A patent/IL276866B/en unknown
-
2021
- 2021-09-29 IL IL286766A patent/IL286766A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018282451B2 (en) | Site-specific antibody-drug conjugation through glycoengineering | |
US20210147524A1 (en) | Fc containing polypeptides with altered glycosylation and reduced effector function | |
DK2895513T3 (da) | Fc-indeholdende polypeptider med ændret glykosylering og reduceret effektorfunktion |